TA878 · STA

Therapeutics for people with COVID-19

Recommended with restrictionsFebruary 2023

Source documents

Interventions

dexamethasone (Ozurdex)
Corticosteroid · Corticosteroid · intravitreal injection
tocilizumab (RoActemra)
IL-6 receptor antagonist · humanised monoclonal antibody that inhibits the cytokine interleukin-6 (IL-6) · intravenous infusion
baricitinib (Olumiant)
Janus kinase inhibitor · Selective inhibition of Janus kinase 1 and 2 · oral
nirmatrelvir plus ritonavir (Paxlovid)
antiviral · protease inhibitor · oral
sotrovimab (Xevudy)
neutralising monoclonal antibody · binds to spike protein via ACE2 expression · intravenous
casirivimab plus imdevimab (Ronapreve)
neutralising monoclonal antibody · neutralising monoclonal antibody · intravenous
molnupiravir (Lagevrio)
antiviral · nucleoside analogue inhibiting RNA-dependent RNA polymerase · oral
remdesivir (Veklury)
antiviral · nucleotide analogue inhibiting RNA-dependent RNA polymerase · intravenous
tixagevimab plus cilgavimab (Evusheld)
neutralising monoclonal antibody · neutralising monoclonal antibody · intramuscular injection

Conditions

covid-19respiratory · mild
covid-19respiratory · severe
covid-19respiratory · acute
mild covid-19respiratory · acute
severe covid-19respiratory · acute
mild covid-19 with high risk of progression to severe diseaserespiratory · acute
severe covid-19 without supplemental oxygenrespiratory · acute
severe covid-19 with supplemental oxygenrespiratory · acute
hospital-onset covid-19respiratory · acute

Comparators

NameType Established Committee preferred
standard carestandard of care
standard care at the time of each trialstandard of care
best supportive carebest supportive care

Clinical trials

TrialDesignPhasePivotal
PANORAMICRCTPhase III
RECOVERYRCTPhase III
SOLIDARITYRCTPhase III
REMAP-CAPRCTPhase III
ACTT-1RCTPhase III
EPIC-HRRCTYes
EPIC-SRRCT
PINETREERCT
COMET-ICERCT

Economic model

mixture cure (assessment_group)
Time horizon: not specified in this chunk
markov
Time horizon: not specified
Cycle length: not specified

Methodological decisions (34)

comparator selection

Definition of high-risk population eligible for treatment

Company: Some trials used broader definitions of risk; age over 50 years considered important

ERG: Assessment group modelled general population survival with starting age 56.6 years and PANORAMIC hospitalisation rates

Committee: McInnes report's definition of high risk is most robust, based on specific risk factors but not age as an independent factor. Concluded that age over 70 years is likely confounded by underlying conditions.

ICER impact: uncertain_direction

comparator selection

Choice of standard care comparator for economic modelling

Company: Not explicitly stated

ERG: Modelled standard care on dexamethasone arm of RECOVERY trial for severe COVID-19 setting

Committee: RECOVERY standard care more generalisable to endemic setting than SOLIDARITY standard care; REMAP-CAP and RECOVERY evidence for tocilizumab considered more generalisable given UK sites and reflection of NHS practice

ICER impact: uncertain_direction

cost assumption

Time to discharge for remdesivir in severe COVID-19

ERG: initially did not include ACTT-1 time to discharge data; later included it following consultee feedback, resulting in large reduction in cost-effectiveness estimates

Committee: acknowledged concerns about generalisability of early pandemic data and supported removal of time to discharge treatment effects

ICER impact: uncertain_direction

cost assumption

Annual per person management costs of long COVID; initially assumed comparable with chronic fatigue syndrome (£1,013); later updated to £2,267 per year (2021/2022 inflated) based on Vos-Vromans et al. 2017

Company: Consultee said AG's base-case underestimated true burden of long COVID and provided alternative higher cost from Vos-Vromans et al. 2017

ERG: AG initially considered costs had minimal impact but provided scenario analyses with increased costs (£2,500); later accepted new evidence and inflated cost to £2,267

Committee: Committee agreed with updated base-case value; agreed scenario analyses had minimal effect on cost-effectiveness estimates but considered new UK-specific evidence should be included if available

ICER impact: negligible

cost assumption

Administration costs for oral antivirals and neutralising monoclonal antibodies; CMDU deployment costs of £410 (oral antivirals) and £820 (monoclonal antibodies); discussion of future primary care delivery and requirements to assess contraindications

Company: Some companies disagreed with using CMDU deployment costs (include secondary care costs); some consultees proposed additional pharmacist costs (£352.49/hour) for nirmatrelvir plus ritonavir interaction assessment or suggested lower costs (£75-£117 for nirmatrelvir plus ritonavir based on e-consultations and telephone triage)

ERG: AG explained changes in administration costs can be evaluated by looking at differences in net monetary benefit; NHS England noted delivery subject to change and costs calculated before nirmatrelvir plus ritonavir implementation

Committee: Committee considered differences in administration costs in relation to net monetary benefit outcomes, noting uncertainty about future delivery models

ICER impact: uncertain_direction

indirect comparison method

Use of network meta-analyses (NMAs) from publicly available sources (COVID-NMA and metaEvidence living systematic reviews) for indirect comparisons across trials

Company: Provided NMA including SOLIDARITY and ACTT-1 trials

ERG: Conducted systematic reviews and NMAs from publicly available sources; updated analysis to include additional trials (SOLIDARITY, ACTT-1) and updated COVID-19 NMA results

Committee: Recognised limitations of systematic reviews that did not adhere to established reviewing methods and missed key trials; accepted updated scenarios including SOLIDARITY and ACTT-1; noted potential for bias from indirect comparison using pairwise analysis rather than full network

ICER impact: uncertain_direction

indirect comparison method

Relative treatment effects for mild COVID-19

Committee: pairwise analysis rather than network NMA introduces potential bias; heterogeneity of trial outputs and generalisability concerns contribute greater uncertainty

ICER impact: increases

model structure

Whether to model separate high-risk subgroups based on specific baseline characteristics or use single definition of high risk

Company: Not explicitly stated

ERG: At first meeting assumed no individual high-risk subgroups modelled by baseline characteristics; at second meeting noted limitations of attempting separate subgroup modelling

Committee: Concluded single definition of high risk should be used. Evidence at subgroup level too limited and uncertain to parameterise differential recommendations. McInnes definition most robust and provides outcomes data from vaccinated people infected with Omicron variants.

ICER impact: uncertain_direction

model structure

Whether to include treatment effects on time to discharge and clinical improvement at 28 days

ERG: included treatment effects on time to discharge

Committee: reasonable to remove treatment effects on time to discharge and clinical improvement at 28 days due to uncertainty in endemic setting

ICER impact: increases

mortality assumption

Assumption about mortality rates for treatment in hospital compared with standard care

Company: Not explicitly stated

ERG: Initially modelled treatment mortality higher than standard care

Committee: Updated assumption to cap mortality rate to equal 1 for low-efficacy scenario in response to consultee feedback regarding implausible mortality outcomes

ICER impact: increases

other

Treatment of mortality assumptions in low-efficacy scenarios for hospital setting

Company: Not explicitly stated

ERG: Initial analysis resulted in treatment having higher mortality risk than standard care in hospital setting

Committee: In response to consultation feedback, AG capped mortality rate to equal 1 for low-efficacy scenario

ICER impact: increases

other

Method for characterising high levels of uncertainty in treatment effects due to changing pandemic context

Company: Not explicitly stated

ERG: Ran scenario analysis using mean and upper/lower confidence limits of efficacy estimates to show mean, lower, and higher efficacy scenarios

Committee: Accepted scenario analysis as attempt to address uncertainty given limitations of probabilistic sensitivity analysis; noted that heterogeneity and generalisability issues made parametrisation for probabilistic sensitivity analysis inappropriate; capped mortality rate to equal 1 for low-efficacy scenario in response to consultee feedback

ICER impact: uncertain_direction

other

Long COVID duration assumptions

Committee: 30% with symptoms at 2 years, 10% at 5 years, 3% at 10 years; maintained assumption of 100% in severe setting and 10% in mild setting despite consultee feedback requesting changes, as alternative evidence not available

ICER impact: negligible

other

Baseline hospitalisation rate for high-risk population defined by McInnes criteria; range between 2.41% (OpenSAFELY untreated eligible using McInnes) and 2.82% (DISCOVER-NOW); 4.00% upper limit for people contraindicated to nirmatrelvir plus ritonavir using advanced renal disease proxy

Company: Not explicitly stated

ERG: AG presented range of rates and acknowledged underestimation in PANORAMIC

Committee: Committee agreed that 0.77% from PANORAMIC was underestimation; concluded hospitalisation rate for McInnes high-risk group likely between 2.41% and 2.82%; 4.00% for contraindicated population

ICER impact: decreases

other

Clinical effectiveness of casirivimab plus imdevimab in severe COVID-19 with supplemental oxygen

Committee: not clinically effective

ICER impact: increases

population generalisability

Clinical evidence collected before Omicron variants became dominant. Hospitalisation and mortality rates now lower with Omicron than earlier variants, making cost-effectiveness estimates higher. Committee considered relevance of clinical data to current endemic context.

Committee: Committee acknowledged limitations of available evidence but considered cost-effectiveness estimates in light of changed epidemiology and lower hospitalisation/mortality rates with Omicron variants.

ICER impact: increases

population generalisability

Marketing authorisations based on evidence from populations with different definitions of high risk (e.g. different age requirements and number of risk factors). Committee acknowledged need to clearly define high risk for treatment eligibility.

Committee: Committee emphasised importance of clear definition of high risk, referencing PANORAMIC trial and independent advisory group report commissioned by Department of Health and Social Care.

ICER impact: uncertain_direction

population generalisability

Generalisability of evidence across trials conducted at different times during pandemic with different variants of concern, vaccinated populations, and natural immunity levels

Company: Not explicitly stated

ERG: Meta-analysing trial results may not be appropriate because weighting may not consider relevance of each trial's context, particularly regarding different variants

Committee: Acknowledged high levels of uncertainty with each treatment effect and context-specific nature of evidence. Used scenario analysis with mean, upper and lower confidence limits rather than probabilistic sensitivity analysis to characterise uncertainty.

ICER impact: uncertain_direction

population generalisability

Concern about age as a protected characteristic being used in treatment recommendations

Company: Age was considered an important risk factor but ongoing debate about appropriate age threshold

ERG: Not specified

Committee: Committee concerned that age-based recommendations could cause inequality. Noted NICE cardiovascular guidance does not include age-based criteria despite it being a recognised risk factor. Age is protected characteristic requiring equity impact assessment.

ICER impact: uncertain_direction

population generalisability

Generalisability of trial evidence to current endemic context with Omicron variant, widespread vaccination, and natural immunity

Company: Not explicitly stated

ERG: Assessed generalisability concerns including changes in population immunity, viral pathogenicity, and supportive care effectiveness

Committee: Mean-efficacy scenarios from pandemic-era trials likely represent ceiling efficacy rather than realistic effectiveness in endemic setting; relative treatment effects would lack generalisability due to interaction with contextual factors; changes in best supportive care and vaccination rates mean limited relative effects

ICER impact: decreases

population generalisability

Whether PANORAMIC hospitalisation rate of 0.77% adequately represents high-risk population

ERG: 0.77% likely underestimation; highest risk groups may be underrepresented

Committee: Hospitalisation rate for McInnes high-risk group is between 2.41% and 2.82% based on OpenSAFELY and DISCOVER-NOW; approximately 4% for those contraindicated to nirmatrelvir plus ritonavir

ICER impact: decreases

population generalisability

EPIC-HR trial population generalisability

Committee: EPIC-HR done in unvaccinated population in earlier wave; EPIC-SR showed non-significant reduction in vaccinated high-risk subgroup; substantial uncertainty due to generalisability concerns; range between mean and lower-efficacy estimates more suited to endemic setting

ICER impact: increases

population generalisability

Remdesivir mortality benefit generalisability to current endemic setting

Committee: SOLIDARITY data and pooled NMA reflect earlier pandemic context; standard care has considerably changed; more certain that relative mortality rate ratio would tend towards 1.00; interpreted evidence cautiously using threshold analysis with mortality rate ratios 0.85 to 1.00

ICER impact: increases

surrogate endpoint validity

Use of network meta-analyses from living systematic reviews with different trial designs, baseline characteristics, geographical locations and pandemic contexts

Company: Company provided alternative NMA including SOLIDARITY trial

ERG: Initial approach used COVID-NMA and metaEvidence living reviews; acknowledged assumptions that relative treatment effects are transferable to current clinical management despite evolving standard care and variants

Committee: Recognised limitations but considered scenario analysis approach attempted to address uncertainty. At consultation, noted heterogeneity and generalisability issues made uncertainty difficult to parameterise for probabilistic sensitivity analysis.

ICER impact: uncertain_direction

surrogate endpoint validity

Adequacy of systematic reviews informing network meta-analyses

Company: Company provided NMA including SOLIDARITY trial and other key trials

ERG: Initial systematic reviews did not adhere to established reviewing methods and missed SOLIDARITY and ACTT-1 trials

Committee: Accepted company-provided NMA including SOLIDARITY and scenarios including ACTT-1 data for remdesivir time to discharge

ICER impact: uncertain_direction

surrogate endpoint validity

Use of in vitro neutralisation assays to predict clinical effectiveness against circulating variants

Company: Noted that in vitro assay methodology may affect interpretation (e.g., ACE2 over-expression in cell lines for sotrovimab)

ERG: Not explicitly stated

Committee: Commissioned in vitro expert advisory group to develop decision framework linking in vitro neutralisation data to clinical outcomes; framework applied to interpret in vitro evidence; recognised that partial reductions in neutralisation are difficult to interpret without additional clinical evidence

ICER impact: uncertain_direction

surrogate endpoint validity

Minimal mortality benefit when HRs close to 1

Committee: for remdesivir and molnupiravir, when potential benefit is minimal (HRs close to 1), stronger clinical evidence needed to justify difference in relative clinical effects; cannot be certain of clinical efficacy

ICER impact: increases

survival extrapolation

Remdesivir mortality benefit threshold analysis with mortality rate ratios between 0.85 and 1.00

Committee: insufficient evidence for meaningful mortality difference vs standard care

ICER impact: uncertain_direction

treatment effect duration

Time to discharge as key driver of cost-effectiveness; removal of treatment effects on time to discharge and clinical improvement at 28 days to account for changing clinical context and heterogeneous population in endemic setting

Company: One consultee highlighted time to discharge data from ACTT-1 should have been included for remdesivir

ERG: AG included time to discharge data for remdesivir (resulting in large reduction in cost-effectiveness estimates); noted data collected during early pandemic stages with generalisability concerns; included scenarios removing treatment effects on time to discharge and clinical improvement

Committee: Committee noted clinical practice differences (time to discharge depends on multiple factors like negative test); considered scenarios removing these treatment effects reasonable but conservative; was uncertain about treatment benefit in endemic setting; concluded it was reasonable to remove these treatment effects

ICER impact: increases

treatment effect waning

Likelihood that neutralising monoclonal antibodies lose effectiveness over time as virus evolves to evade treatments

Company: Emphasised that sotrovimab's effectiveness depends on ACE2 expression levels and in vitro assay methodology may underestimate clinical efficacy

ERG: Not explicitly stated separately

Committee: Casirivimab plus imdevimab and tixagevimab plus cilgavimab unlikely to retain sufficient neutralisation activity against most variants circulating at time of evaluation; sotrovimab showed ambiguous in vitro evidence with uncertainty about effectiveness against BQ.1 and BQ.1.1

ICER impact: decreases

treatment effect waning

Effectiveness of neutralising monoclonal antibodies against evolving variants

Company: sotrovimab's effectiveness depends on ACE2 expression levels; in vitro over-expression may underestimate neutralising ability

Committee: casirivimab plus imdevimab and tixagevimab plus cilgavimab unlikely to retain sufficient neutralisation activity; sotrovimab clinical effectiveness likely reduced against BA.5 with uncertainty on BQ.1 and BQ.1.1; effectiveness requires continuous monitoring

ICER impact: increases

utility source

Use of UK age- and sex-adjusted utility values (EQ-5D-3L) for baseline utility estimates; no additional utility decrements for mild COVID-19 without long COVID; use of age- and sex-adjusted UK general population utility instead

Company: Stakeholders critiqued this assumption saying it may not capture full benefit of treatments compared with standard care and disadvantaged community-based treatments

ERG: AG agreed this was a simplified assumption but scenario analysis showed it had limited impact on final ICERs

Committee: Committee agreed with AG's assumption and acknowledged minor impact on ICERs

ICER impact: negligible

utility source

Use of utility decrements from cost-effectiveness analysis of remdesivir (originally from population with recurrent Clostridioides difficile infection and influenza) for severe COVID-19 setting; same in-hospital utility decrements applied across ordinal scales 3 to 5

Company: Stakeholders critiqued use of utility decrements from non-COVID-19 population; proposed alternative approach using COVID-19 severity-specific vignettes with EQ-5D-3L questionnaires; highlighted recent COVID-19 utility-specific systematic reviews

ERG: AG said vignette study would not be possible due to restricted timelines; did not find alternative COVID-19 utility decrements from stakeholder-suggested systematic reviews

Committee: Not explicitly stated in this section

ICER impact: uncertain_direction

utility source

Use of post-discharge long COVID utility decrements from Evans et al. 2022; same utility decrement assumed regardless of ordinal scale status at hospital admission

Company: Stakeholders suggested alternative source of post-discharge utility decrements split by history of ordinal scale status

ERG: AG explained model structure unable to allocate post-discharge utility based on historical ordinal scale admission status; also that utility decrements only applied for duration of long COVID and not key driver of ICERs

Committee: Committee agreed with AG's rationale and long COVID utility decrement assumptions

ICER impact: negligible

Evidence gaps

no direct comparisonDifferent trials conducted at different times comparing individual treatments against evolving standard care; meta-analysis assumes transferability of relative treatment effects across different pandemic contexts and variants
short follow upTrials conducted at different stages of pandemic with changing vaccinations and natural immunity levels
otherLimited evidence at subgroup level for separate high-risk group recommendations; would require additional functionality, clinical and cost inputs
no direct comparisonIndirect comparisons between treatments based on pairwise analysis rather than full network meta-analysis, with potential for bias
short follow upClinical trial evidence from pandemic setting (early pandemic for some treatments) may not reflect effectiveness in current endemic context with Omicron variant, widespread vaccination, and natural immunity
surrogate not validatedIn vitro neutralisation assays used to predict clinical effectiveness against emerging variants; framework developed to link in vitro data to clinical outcomes but clinical evidence unavailable for validation against newly circulating variants
no uk dataTrial populations and contexts differ significantly (different time points in pandemic, variants, vaccination status, standard care practices); generalisability to current endemic setting highly uncertain, particularly for remdesivir and neutralising monoclonal antibodies
no uk dataPANORAMIC study population had lower risk of severe disease than McInnes-defined high-risk population
no uk dataNo clinical evidence available for remdesivir in current endemic setting with widely vaccinated and naturally immune population and Omicron variant
no direct comparisonNo direct comparisons between treatments in mild and severe COVID-19 settings; reliance on indirect treatment comparisons with pairwise analysis
short follow upTime to discharge evidence from early pandemic stages (ACTT-1) has substantial generalisability concerns due to changed clinical context
surrogate not validatedIn vitro neutralisation activity data for monoclonal antibodies cannot reliably predict clinical efficacy against evolving variants without additional clinical evidence
immature overall survivalInsufficient survival benefit data for remdesivir; no events in either arm for some analyses
otherEPIC-SR results preliminary, published on company website only rather than peer-reviewed journal
short follow upTime to discharge data collected during early stages of pandemic with substantial generalisability concerns due to changed context of care in endemic setting
no direct comparisonUncertain relative treatment effects for casirivimab plus imdevimab, tixagevimab plus cilgavimab and molnupiravir in reducing hospitalisation or mortality
otherUncertain clinical effectiveness of casirivimab plus imdevimab; uncertainty about remdesivir effectiveness in severe COVID-19 setting without supplemental oxygen

Commercial arrangement

simple discount pas · confidential · critical for recommendation

Special considerations

Innovation acknowledged Equality issues raised